The funding will go toward created a summer program called the University of Houston Cardiovascular Undergraduate Research Experience, or UH-CURE. Photo via UH.edu

University of Houston professors have received a nearly $800,000 grant to create a new summer program that will support diverse future researchers.

The National Heart, Lung, and Blood Institute provided $792,900 in grant funding to Bradley McConnell, professor of pharmacology at the UH College of Pharmacy, and Tho Tran, research assistant professor of chemistry at the UH College of Natural Sciences and Mathematics.

The funding will go toward created a summer program called the University of Houston Cardiovascular Undergraduate Research Experience, or UH-CURE. Ten undergraduate students per year will be selected for five years in cardiovascular research across disciplinary lines.

"We are so grateful to be able to provide talented students across the U.S. an opportunity to experience our excellent cardiovascular research environment,” Tran says in a news release. “We want UH-CURE participants to gain confidence in their research abilities through our hands-on approach and the skillset to navigate future challenges through our professional training.”

The goal is to increase students’ interest in cardiovascular research, and students have the opportunity to receive a $6,000 stipend, travel to a globally recognized cardiovascular research conference, and take part in on-campus housing and a food allowance. The summer program will also try to develop research skills, increase awareness of transdisciplinary research, promote diversity and collaborations, cultivate transferable skills necessary for succeeding in graduate school and help facilitate undergraduate students to pursue further training in cardiovascular research.

The program will integrate students into a research lab where they will learn research skills, data analysis, and research integrity. The program will be under the mentorship of a faculty member from across UH’s colleges, and include workshop and enrichment activities.

McConnell and Tran previously formed the American Heart Association-funded UH-HEART pilot program, which focused on cardiovascular research. They expanded on that initiative with UH-CURE, which includes cardiovascular research across disciplinary lines from community engagement and population-based research to basic, translational, and applied research. UH-CURE also helps prepare for careers in cardiovascular research.

“We all know that a diverse environment leads to a much better generation of ideas and solutions,” Tran adds. “We hope to bring that strength to the future of cardiovascular research through our students.”

Tho Tran (left) and Bradley McConnell are professors at UH. Photo via UH.edu

Moonflower Farms grows lettuce hydroponically. Courtesy of Moonflower Farms

Innovative Houston urban farm scores national award for green work

to the moon

A Houston urban farm has earned national recognition for its innovative approach to water conservation. Moonflower Farms won the American Heart Association's Foodscape Innovation Excellence Award, which recognizes positive changes in the foodscape, a term for all of the places where food is produced, purchased, or consumed.

The Heart Association selected Moonflower's submission, titled "Sustainable Farming Through Water Conservation," from 26 entries. Dallas' Restorative Farms earns the Foodscape Innovation Consumer Choice Award.

"These two innovations demonstrate a way of producing food that promotes affordability and equitable access, and the American Heart Association is proud to recognize these efforts," AHA chief medical officer for prevention Eduardo Sanchez said in a release.

Located in a 20,000-square-foot greenhouse south of downtown, Moonflower operates what it describes as Houston's first vertical indoor farm. The method both reduces the amount of space needed to grow the farm's microgreens, lettuces, herbs and edible flowers and it eliminates the disruptions caused by adverse weather conditions, which allows the farm to produce year round.

Moonflower uses a closed-loop system for capturing rainwater to feed its crops. The water is treated and oxygenated so that it can be reused. Not having to pay for water from the City of Houston allows the farm to operate more economically and sell its produce at an affordable price to restaurants and individuals.

"Our hydroponic farm uses 90-percent less water than conventional farms," Moonflower founder and CEO Federico Marques said in a statement. "We provide year-round produce to residents in historically underserved communities and donate produce to local charitable food systems."

One of those charities is Houston non-profit Second Servings, which "rescues" food from restaurants and events and distributes it to food pantries and other resources.

"The donations we receive from Moonflower Farms are incredible," Second Servings founder and president Barbara Bronstein said. "Their hydroponically grown greens are so appreciated by the needy Houstonians we serve, who lack affordable, convenient access to fresh produce."

Recently, Moonflower introduced a SupaGreens subscription box that allows customers to purchase greens weekly, bimonthly, or monthly. The box is delivered directly to consumers.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.